Risk Stratification for Hepatocellular Carcinoma in Patients with Non-alcoholic Fatty Liver Disease

Purposeof Review This review aims to supply up-to-date recommendations on risk stratification for hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). Recent Findings NAFLD is the most rapidly growing cause of HCC in the USA. HCC surveillance in patients with NA...

Full description

Saved in:
Bibliographic Details
Published in:Current hepatology reports 2023-03, Vol.22 (1), p.1-8
Main Authors: Truong, Emily, Han, Cheng, Muthiah, Mark, Noureddin, Mazen
Format: Article
Language:English
Subjects:
Hepatic Cancer (N Parikh
Hepatology
Medicine
Medicine & Public Health
Section Editor
Topical Collection on Hepatic Cancer
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purposeof Review This review aims to supply up-to-date recommendations on risk stratification for hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). Recent Findings NAFLD is the most rapidly growing cause of HCC in the USA. HCC surveillance in patients with NAFLD remains a clinical challenge due to the large global burden of NAFLD, limitations in surveillance modalities, and the widely recognized possibility of HCC development in NAFLD in the absence of cirrhosis. Summary Based on fibrosis staging, HCC screening in NAFLD is recommended in cirrhosis, considered in advanced fibrosis, and not recommended in the absence of advanced fibrosis. Though liver biopsy is the gold standard for staging, evidence of advanced fibrosis warranting HCC surveillance in NAFLD can be based on 2 concordant noninvasive tests. Those meeting recommended criteria for HCC surveillance should undergo imaging with or without serum α-fetoprotein levels every 6 months at minimum.
ISSN:2195-9595
2195-9595
DOI:10.1007/s11901-023-00595-7